F2 - coagulation factor II Gene
Species: Rattus norvegicus
Summary
Predicted to enable several functions, including heparin binding activity; lipopolysaccharide binding activity; and serine-type endopeptidase activity. Involved in several processes, including cellular response to mechanical stimulus; response to thyrotropin-releasing hormone; and response to thyroxine. Located in collagen-containing extracellular matrix and extracellular space. Used to study several diseases, including atherosclerosis; end stage renal disease; hyperhomocysteinemia; obesity; and thrombophilia (multiple). Biomarker of Bacterial pneumonia; brain edema; calcium oxalate nephrolithiasis; and thrombosis. Human ortholog(s) of this gene implicated in several diseases, including X-linked recessive disease (multiple); appendicitis; artery disease (multiple); autoimmune disease (multiple); and thrombophilia (multiple). Orthologous to human F2 (coagulation factor II, Thrombin). [provided by Alliance of Genome Resources, Apr 2022]
F2 Products (1)
| mRNA | Protein | Name |
|---|---|---|
| NM_022924.2 | NP_075213.2 | prothrombin precursor |
Gene Ontology
- Biological Process
- Cellular Component
| Biological Process GO Annotation | Evidence | References | Source |
|---|---|---|---|
| involved in cellular response to mechanical stimulus |
IEP
IEP: Inferred from expression pattern
|
22915765 | RGD |
| involved in positive regulation of blood coagulation |
IMP
IMP: Inferred from mutant phenotype
|
20664909 | RGD |
| involved in response to Thyroglobulin triiodothyronine |
IEP
IEP: Inferred from expression pattern
|
18336749 | RGD |
| involved in response to inactivity |
IEP
IEP: Inferred from expression pattern
|
16078333 | RGD |
| involved in response to thyrotropin-releasing hormone |
IEP
IEP: Inferred from expression pattern
|
18336749 | RGD |
| involved in response to thyroxine |
IEP
IEP: Inferred from expression pattern
|
18336749 | RGD |
| Cellular Component GO Annotation | Evidence | References | Source |
|---|---|---|---|
| located in collagen-containing extracellular matrix |
IDA
IDA: Inferred from direct assay
|
21191574 | RGD |
| located in extracellular space |
IDA
IDA: Inferred from direct assay
|
16078333 | RGD |
| Protein Preferred Names | Protein Names | |
|---|---|---|
|
prothrombin |
|
Recombinant F2 Proteins
| Cat. No. | Product Name | Accession | Purity |
|---|---|---|---|
| HY-P74241 | Coagulation Factor II/F2 Protein, Rat (HEK293, His) | P18292/NP_075213.2 (Q25-R617) | ≥ 90%, as determined by Bis-Tris PAGE. |
Related Agents
- Approval
- Clinical Phase
- Pre-clinical Phase
Approval
| Cat. No. | Product Name |
Effect
|
Purity |
Rare Diseases
|
|---|---|---|---|---|
| HY-12956 | Dinoprost | 99.84% | Unkown | |
| HY-B0577 | Latanoprost | Agonist | 99.85% | Unkown |
| HY-113756A | Latanoprost acid | Agonist | 98.77% | Unkown |
| HY-19518 | Latanoprostene bunod | Control | 99.75% | Unkown |
| HY-12956A | Dinoprost tromethamine salt | 98.0% | Unkown | |
| HY-128428 | Carboprost | 99.84% | Unkown | |
| HY-A0195 | Carboprost tromethamine | 99.85% | Unkown | |
| HY-106916 | Unoprostone | Activator | 99.0% | Unkown |
| HY-116733 | Tafluprost ethyl ester | Agonist | / | Unkown |
| HY-B0577R | Latanoprost (Standard) | Agonist | / | Unkown |
| HY-19518R | Latanoprostene bunod (Standard) | Control | / | Unkown |
Clinical Phase
| Cat. No. | Product Name |
Effect
|
Purity |
Phase |
|---|---|---|---|---|
| HY-141637 | 2-Deoxy-2-fluoro-D-glucose | 99.89% | Phase 4 | |
| HY-129397 | 2,3-Dinor-11beta-prostaglandin F2alpha | / | Phase 4 | |
| HY-106037 | PGF2α-isopropyl ester | / | Phase 3 | |
| HY-17644 | Redaporfin | 99.44% | Phase 2 | |
| HY-112284 | Ebopiprant | Antagonist | 98.65% | Phase 2 |
| Cat. No. | Product Name |
Effect
|
Purity |
Phase |
|---|---|---|---|---|
| HY-P99712 | Lonigutamab | 95.00% | Phase 2 | |
| HY-P991422 | Stromab | Inhibitor | 99.28% | Phase 2 |
Pre-clinical Phase
| Cat. No. | Product Name |
Effect
|
Purity |
Rare Diseases
|
|---|---|---|---|---|
| HY-P990284 | Anti-Mouse CD205 Antibody (NLDC-145) | 95% | Unkown | |
| HY-P99891 | Rovelizumab | Inhibitor | 97.23% | Unkown |
| HY-P990597 | HuGAL-F2 | Inhibitor | 98.30% | Unkown |
| HY-P990823 | Anti-Mouse PD-L1/B7-H1 Antibody (10F.2H11) | Inhibitor | / | Unkown |